# PeptideScanner evidence objects: Dasiglucagon

Every published version of the records placed with Dasiglucagon, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json. Selected public evidence only; not medical advice.

- Objects: 20
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct02916251-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT02916251

> PeptideScanner retained ClinicalTrials.gov record NCT02916251 at 2026-11-16T01:42:39.027Z. Its registry update date was 2017-04-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct02916251-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02916251-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct02916251-dasiglucagon-v1
- Content SHA-256: `ec9b011ef759f58f8c8ae0aff4d66c758d14df87cb4cc8206c7692476a4f225d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02916251 ([`ctg-observation-nct02916251-2017-04-21-a503723a64d9`](#source-ctg-observation-nct02916251-2017-04-21-a503723a64d9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02916251 at 2026-11-16T01:42:39.027Z. Its registry update date was 2017-04-21, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct02916251-2017-04-21-a503723a64d9`](#source-ctg-observation-nct02916251-2017-04-21-a503723a64d9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02916251 at 2026-11-16T01:42:39.027Z. Its registry update date was 2017-04-21, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct02916251-2017-04-21-a503723a64d9`](#source-ctg-observation-nct02916251-2017-04-21-a503723a64d9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02916251-2017-04-21-a503723a64d9`](#source-ctg-observation-nct02916251-2017-04-21-a503723a64d9))

### Sources

<a id="source-ctg-observation-nct02916251-2017-04-21-a503723a64d9"></a>
- **ClinicalTrials.gov record NCT02916251 · retained source version 2017-04-21:a503723a64d931b309ca704e234c9694537451756e8acf1bfd115eafb50b7dfa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02916251) (`ctg-observation-nct02916251-2017-04-21-a503723a64d9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02916251." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct02916251-dasiglucagon-v1 SHA-256: ec9b011ef759f58f8c8ae0aff4d66c758d14df87cb4cc8206c7692476a4f225d.

---

<a id="clinicaltrials-gov-nct03216226-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03216226

> PeptideScanner retained ClinicalTrials.gov record NCT03216226 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-04, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03216226-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03216226-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03216226-dasiglucagon-v1
- Content SHA-256: `519dc5accc9e3a80bdea86c1b87debf44262490bc34fcad841c06d9b54f023c8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03216226 ([`ctg-observation-nct03216226-2021-05-04-7622ec6df9bc`](#source-ctg-observation-nct03216226-2021-05-04-7622ec6df9bc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03216226 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-04, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03216226-2021-05-04-7622ec6df9bc`](#source-ctg-observation-nct03216226-2021-05-04-7622ec6df9bc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03216226 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-04, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03216226-2021-05-04-7622ec6df9bc`](#source-ctg-observation-nct03216226-2021-05-04-7622ec6df9bc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03216226-2021-05-04-7622ec6df9bc`](#source-ctg-observation-nct03216226-2021-05-04-7622ec6df9bc))

### Sources

<a id="source-ctg-observation-nct03216226-2021-05-04-7622ec6df9bc"></a>
- **ClinicalTrials.gov record NCT03216226 · retained source version 2021-05-04:7622ec6df9bc4b59f86510b40378fbc0a764acd07559e09f3cdef60f99dbd80b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03216226) (`ctg-observation-nct03216226-2021-05-04-7622ec6df9bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03216226." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03216226-dasiglucagon-v1 SHA-256: 519dc5accc9e3a80bdea86c1b87debf44262490bc34fcad841c06d9b54f023c8.

---

<a id="clinicaltrials-gov-nct03378635-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03378635

> PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03378635-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03378635-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03378635-dasiglucagon-v1
- Content SHA-256: `b11968fd5a4f213e0eebe519714997f1f790dad9e9cd3568d62419b80d570b3b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03378635 ([`ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d`](#source-ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d`](#source-ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d`](#source-ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d`](#source-ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d))

### Sources

<a id="source-ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d"></a>
- **ClinicalTrials.gov record NCT03378635 · retained source version 2021-06-10:1c32bb39cf1d3bbbf40ac24cbaf9de7296f4bb2a58493a452d42f33f61a3359e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03378635) (`ctg-observation-nct03378635-2021-06-10-1c32bb39cf1d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03378635." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03378635-dasiglucagon-v1 SHA-256: b11968fd5a4f213e0eebe519714997f1f790dad9e9cd3568d62419b80d570b3b.

---

<a id="clinicaltrials-gov-nct03667053-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03667053

> PeptideScanner retained ClinicalTrials.gov record NCT03667053 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03667053-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03667053-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03667053-dasiglucagon-v1
- Content SHA-256: `10e5f712dc446c7a50c378d312ec2c6559f3053ab283ad776ffda3be870a6e60`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03667053 ([`ctg-observation-nct03667053-2021-06-30-7864d7129e96`](#source-ctg-observation-nct03667053-2021-06-30-7864d7129e96))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03667053 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03667053-2021-06-30-7864d7129e96`](#source-ctg-observation-nct03667053-2021-06-30-7864d7129e96))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03667053 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03667053-2021-06-30-7864d7129e96`](#source-ctg-observation-nct03667053-2021-06-30-7864d7129e96))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03667053-2021-06-30-7864d7129e96`](#source-ctg-observation-nct03667053-2021-06-30-7864d7129e96))

### Sources

<a id="source-ctg-observation-nct03667053-2021-06-30-7864d7129e96"></a>
- **ClinicalTrials.gov record NCT03667053 · retained source version 2021-06-30:7864d7129e96471130ac5a297635596f664a5470a31732cdeb0fface4e0ffa76** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03667053) (`ctg-observation-nct03667053-2021-06-30-7864d7129e96`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03667053." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03667053-dasiglucagon-v1 SHA-256: 10e5f712dc446c7a50c378d312ec2c6559f3053ab283ad776ffda3be870a6e60.

---

<a id="clinicaltrials-gov-nct03688711-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03688711

> PeptideScanner retained ClinicalTrials.gov record NCT03688711 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-19, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03688711-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03688711-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03688711-dasiglucagon-v1
- Content SHA-256: `829d8ce8b735a025eb7fe73ac8140945df5a0a094842db6c76a45ef81c8e3f2c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03688711 ([`ctg-observation-nct03688711-2021-05-19-72150fdcadb1`](#source-ctg-observation-nct03688711-2021-05-19-72150fdcadb1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03688711 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-19, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03688711-2021-05-19-72150fdcadb1`](#source-ctg-observation-nct03688711-2021-05-19-72150fdcadb1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03688711 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-19, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03688711-2021-05-19-72150fdcadb1`](#source-ctg-observation-nct03688711-2021-05-19-72150fdcadb1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03688711-2021-05-19-72150fdcadb1`](#source-ctg-observation-nct03688711-2021-05-19-72150fdcadb1))

### Sources

<a id="source-ctg-observation-nct03688711-2021-05-19-72150fdcadb1"></a>
- **ClinicalTrials.gov record NCT03688711 · retained source version 2021-05-19:72150fdcadb10f645b9ae62e6b7a308a50df05150c91f7a4eea1f9005818e00d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03688711) (`ctg-observation-nct03688711-2021-05-19-72150fdcadb1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03688711." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03688711-dasiglucagon-v1 SHA-256: 829d8ce8b735a025eb7fe73ac8140945df5a0a094842db6c76a45ef81c8e3f2c.

---

<a id="clinicaltrials-gov-nct03735225-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03735225

> PeptideScanner retained ClinicalTrials.gov record NCT03735225 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03735225-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-03-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03735225-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03735225-dasiglucagon-v1
- Content SHA-256: `d20df400c94b56042adfef950c5c5c1608cd935379d715232c0e830291babe1f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03735225 ([`ctg-observation-nct03735225-2021-03-23-f181bfc79d4c`](#source-ctg-observation-nct03735225-2021-03-23-f181bfc79d4c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03735225 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03735225-2021-03-23-f181bfc79d4c`](#source-ctg-observation-nct03735225-2021-03-23-f181bfc79d4c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03735225 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03735225-2021-03-23-f181bfc79d4c`](#source-ctg-observation-nct03735225-2021-03-23-f181bfc79d4c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03735225-2021-03-23-f181bfc79d4c`](#source-ctg-observation-nct03735225-2021-03-23-f181bfc79d4c))

### Sources

<a id="source-ctg-observation-nct03735225-2021-03-23-f181bfc79d4c"></a>
- **ClinicalTrials.gov record NCT03735225 · retained source version 2021-03-23:f181bfc79d4c0e84b2186835ddeaaa45a891daa374da59ac44e99b7a3d4992e9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03735225) (`ctg-observation-nct03735225-2021-03-23-f181bfc79d4c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03735225." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03735225-dasiglucagon-v1 SHA-256: d20df400c94b56042adfef950c5c5c1608cd935379d715232c0e830291babe1f.

---

<a id="clinicaltrials-gov-nct03777176-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03777176

> PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03777176-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-12-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03777176-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03777176-dasiglucagon-v1
- Content SHA-256: `377cac9f80ed234c39eb4712d43cccd749d3b0f6af9607d839b6196a3cfdafbf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03777176 ([`ctg-observation-nct03777176-2023-12-13-560aece6840a`](#source-ctg-observation-nct03777176-2023-12-13-560aece6840a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03777176-2023-12-13-560aece6840a`](#source-ctg-observation-nct03777176-2023-12-13-560aece6840a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03777176-2023-12-13-560aece6840a`](#source-ctg-observation-nct03777176-2023-12-13-560aece6840a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03777176-2023-12-13-560aece6840a`](#source-ctg-observation-nct03777176-2023-12-13-560aece6840a))

### Sources

<a id="source-ctg-observation-nct03777176-2023-12-13-560aece6840a"></a>
- **ClinicalTrials.gov record NCT03777176 · retained source version 2023-12-13:560aece6840a229a008d70563761aadc2e0422f2688d4430af424f154cb7f5c3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03777176) (`ctg-observation-nct03777176-2023-12-13-560aece6840a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03777176." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03777176-dasiglucagon-v1 SHA-256: 377cac9f80ed234c39eb4712d43cccd749d3b0f6af9607d839b6196a3cfdafbf.

---

<a id="clinicaltrials-gov-nct03840278-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03840278

> PeptideScanner retained ClinicalTrials.gov record NCT03840278 at 2026-11-16T01:42:39.027Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03840278-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-12-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03840278-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03840278-dasiglucagon-v1
- Content SHA-256: `933c7f1b5f2aadd371ec1d11ce808ae8266c1c2d8e94d221215a699576aa0293`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03840278 ([`ctg-observation-nct03840278-2019-12-16-c92d031e1c9d`](#source-ctg-observation-nct03840278-2019-12-16-c92d031e1c9d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03840278 at 2026-11-16T01:42:39.027Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03840278-2019-12-16-c92d031e1c9d`](#source-ctg-observation-nct03840278-2019-12-16-c92d031e1c9d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03840278 at 2026-11-16T01:42:39.027Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03840278-2019-12-16-c92d031e1c9d`](#source-ctg-observation-nct03840278-2019-12-16-c92d031e1c9d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03840278-2019-12-16-c92d031e1c9d`](#source-ctg-observation-nct03840278-2019-12-16-c92d031e1c9d))

### Sources

<a id="source-ctg-observation-nct03840278-2019-12-16-c92d031e1c9d"></a>
- **ClinicalTrials.gov record NCT03840278 · retained source version 2019-12-16:c92d031e1c9da2691172c843abed885c3d8f02562f1b83ef31fc565ae6b9d501** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03840278) (`ctg-observation-nct03840278-2019-12-16-c92d031e1c9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03840278." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03840278-dasiglucagon-v1 SHA-256: 933c7f1b5f2aadd371ec1d11ce808ae8266c1c2d8e94d221215a699576aa0293.

---

<a id="clinicaltrials-gov-nct03895697-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03895697

> PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03895697-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-02-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03895697-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03895697-dasiglucagon-v1
- Content SHA-256: `4ae43df41d35bc9ec46eb51a61f9ac652e9dabb9da37298e98ca59a5be2f35c1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03895697 ([`ctg-observation-nct03895697-2023-02-21-e9d76518c161`](#source-ctg-observation-nct03895697-2023-02-21-e9d76518c161))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03895697-2023-02-21-e9d76518c161`](#source-ctg-observation-nct03895697-2023-02-21-e9d76518c161))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03895697-2023-02-21-e9d76518c161`](#source-ctg-observation-nct03895697-2023-02-21-e9d76518c161))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03895697-2023-02-21-e9d76518c161`](#source-ctg-observation-nct03895697-2023-02-21-e9d76518c161))

### Sources

<a id="source-ctg-observation-nct03895697-2023-02-21-e9d76518c161"></a>
- **ClinicalTrials.gov record NCT03895697 · retained source version 2023-02-21:e9d76518c161adff9ca9f090abdc613b0238f31abf169bedba230d004998f2d5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03895697) (`ctg-observation-nct03895697-2023-02-21-e9d76518c161`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03895697." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03895697-dasiglucagon-v1 SHA-256: 4ae43df41d35bc9ec46eb51a61f9ac652e9dabb9da37298e98ca59a5be2f35c1.

---

<a id="clinicaltrials-gov-nct03941236-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03941236

> PeptideScanner retained ClinicalTrials.gov record NCT03941236 at 2026-11-16T01:42:39.027Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03941236-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03941236-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03941236-dasiglucagon-v1
- Content SHA-256: `6d6dfcb3efc2e83d5c7ab7e0fd8072c3ccd3e15f80ddff01be1acf4067b055d9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03941236 ([`ctg-observation-nct03941236-2026-08-03-e7b018d362a9`](#source-ctg-observation-nct03941236-2026-08-03-e7b018d362a9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03941236 at 2026-11-16T01:42:39.027Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03941236-2026-08-03-e7b018d362a9`](#source-ctg-observation-nct03941236-2026-08-03-e7b018d362a9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03941236 at 2026-11-16T01:42:39.027Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03941236-2026-08-03-e7b018d362a9`](#source-ctg-observation-nct03941236-2026-08-03-e7b018d362a9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03941236-2026-08-03-e7b018d362a9`](#source-ctg-observation-nct03941236-2026-08-03-e7b018d362a9))

### Sources

<a id="source-ctg-observation-nct03941236-2026-08-03-e7b018d362a9"></a>
- **ClinicalTrials.gov record NCT03941236 · retained source version 2026-08-03:e7b018d362a957f40fccd63f0a42e1493b76151524ab8981b5f6714b84c6cfeb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03941236) (`ctg-observation-nct03941236-2026-08-03-e7b018d362a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03941236." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03941236-dasiglucagon-v1 SHA-256: 6d6dfcb3efc2e83d5c7ab7e0fd8072c3ccd3e15f80ddff01be1acf4067b055d9.

---

<a id="clinicaltrials-gov-nct03984370-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT03984370

> PeptideScanner retained ClinicalTrials.gov record NCT03984370 at 2026-11-16T01:42:39.027Z. Its registry update date was 2020-03-31, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct03984370-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-03-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03984370-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03984370-dasiglucagon-v1
- Content SHA-256: `4d932b7a0b413c38fa08c1d1d00188212ea4254c33e5499b0d30ffb2a059834f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03984370 ([`ctg-observation-nct03984370-2020-03-31-d447fb20759d`](#source-ctg-observation-nct03984370-2020-03-31-d447fb20759d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03984370 at 2026-11-16T01:42:39.027Z. Its registry update date was 2020-03-31, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03984370-2020-03-31-d447fb20759d`](#source-ctg-observation-nct03984370-2020-03-31-d447fb20759d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03984370 at 2026-11-16T01:42:39.027Z. Its registry update date was 2020-03-31, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct03984370-2020-03-31-d447fb20759d`](#source-ctg-observation-nct03984370-2020-03-31-d447fb20759d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03984370-2020-03-31-d447fb20759d`](#source-ctg-observation-nct03984370-2020-03-31-d447fb20759d))

### Sources

<a id="source-ctg-observation-nct03984370-2020-03-31-d447fb20759d"></a>
- **ClinicalTrials.gov record NCT03984370 · retained source version 2020-03-31:d447fb20759d62ccbf04cca9ab1d5c887601a4128804690852cb6c2391aeefbe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03984370) (`ctg-observation-nct03984370-2020-03-31-d447fb20759d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03984370." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct03984370-dasiglucagon-v1 SHA-256: 4d932b7a0b413c38fa08c1d1d00188212ea4254c33e5499b0d30ffb2a059834f.

---

<a id="clinicaltrials-gov-nct04172441-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT04172441

> PeptideScanner retained ClinicalTrials.gov record NCT04172441 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct04172441-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-03-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04172441-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct04172441-dasiglucagon-v1
- Content SHA-256: `6a317d51b83d666e63d8f94ed17d659f2d693994f26e979b8be98c2080d5eed8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04172441 ([`ctg-observation-nct04172441-2025-03-14-cad3765e5e0d`](#source-ctg-observation-nct04172441-2025-03-14-cad3765e5e0d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04172441 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct04172441-2025-03-14-cad3765e5e0d`](#source-ctg-observation-nct04172441-2025-03-14-cad3765e5e0d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04172441 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct04172441-2025-03-14-cad3765e5e0d`](#source-ctg-observation-nct04172441-2025-03-14-cad3765e5e0d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04172441-2025-03-14-cad3765e5e0d`](#source-ctg-observation-nct04172441-2025-03-14-cad3765e5e0d))

### Sources

<a id="source-ctg-observation-nct04172441-2025-03-14-cad3765e5e0d"></a>
- **ClinicalTrials.gov record NCT04172441 · retained source version 2025-03-14:cad3765e5e0dc97af8b9225e3521e21bc544312f3a351a1b1c9fa2af45252383** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04172441) (`ctg-observation-nct04172441-2025-03-14-cad3765e5e0d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04172441." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct04172441-dasiglucagon-v1 SHA-256: 6a317d51b83d666e63d8f94ed17d659f2d693994f26e979b8be98c2080d5eed8.

---

<a id="clinicaltrials-gov-nct04449692-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT04449692

> PeptideScanner retained ClinicalTrials.gov record NCT04449692 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct04449692-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-02-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04449692-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct04449692-dasiglucagon-v1
- Content SHA-256: `bc79a222e599fe724340774dc9806f6d9396be760b2c61bfcd5c45b41c0deae0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04449692 ([`ctg-observation-nct04449692-2021-02-09-c642e236627f`](#source-ctg-observation-nct04449692-2021-02-09-c642e236627f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04449692 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct04449692-2021-02-09-c642e236627f`](#source-ctg-observation-nct04449692-2021-02-09-c642e236627f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04449692 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct04449692-2021-02-09-c642e236627f`](#source-ctg-observation-nct04449692-2021-02-09-c642e236627f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04449692-2021-02-09-c642e236627f`](#source-ctg-observation-nct04449692-2021-02-09-c642e236627f))

### Sources

<a id="source-ctg-observation-nct04449692-2021-02-09-c642e236627f"></a>
- **ClinicalTrials.gov record NCT04449692 · retained source version 2021-02-09:c642e236627f0a116c70beaf8619fa1b1327d7e8d11a38f6bc8d1fa389f39469** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04449692) (`ctg-observation-nct04449692-2021-02-09-c642e236627f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04449692." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct04449692-dasiglucagon-v1 SHA-256: bc79a222e599fe724340774dc9806f6d9396be760b2c61bfcd5c45b41c0deae0.

---

<a id="clinicaltrials-gov-nct04764968-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT04764968

> PeptideScanner retained ClinicalTrials.gov record NCT04764968 at 2026-11-16T01:42:39.027Z. Its registry update date was 2022-09-07, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct04764968-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04764968-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct04764968-dasiglucagon-v1
- Content SHA-256: `243e4905203b969c824c5cf61959e1ef031d58f194ff53b820ab665a9dbb9685`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04764968 ([`ctg-observation-nct04764968-2022-09-07-c5701bf0b833`](#source-ctg-observation-nct04764968-2022-09-07-c5701bf0b833))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04764968 at 2026-11-16T01:42:39.027Z. Its registry update date was 2022-09-07, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct04764968-2022-09-07-c5701bf0b833`](#source-ctg-observation-nct04764968-2022-09-07-c5701bf0b833))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04764968 at 2026-11-16T01:42:39.027Z. Its registry update date was 2022-09-07, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct04764968-2022-09-07-c5701bf0b833`](#source-ctg-observation-nct04764968-2022-09-07-c5701bf0b833))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04764968-2022-09-07-c5701bf0b833`](#source-ctg-observation-nct04764968-2022-09-07-c5701bf0b833))

### Sources

<a id="source-ctg-observation-nct04764968-2022-09-07-c5701bf0b833"></a>
- **ClinicalTrials.gov record NCT04764968 · retained source version 2022-09-07:c5701bf0b833b70ed61587e7b5d79d6f6448d8b6510bb5bee61718238cc9f878** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04764968) (`ctg-observation-nct04764968-2022-09-07-c5701bf0b833`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04764968." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct04764968-dasiglucagon-v1 SHA-256: 243e4905203b969c824c5cf61959e1ef031d58f194ff53b820ab665a9dbb9685.

---

<a id="clinicaltrials-gov-nct04836273-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT04836273

> PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct04836273-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-02-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04836273-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct04836273-dasiglucagon-v1
- Content SHA-256: `45239e22956babbdcc69617670188c0bda48de7528fa7f55b1c2250b9651a92a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04836273 ([`ctg-observation-nct04836273-2023-02-02-3f1d5891cd73`](#source-ctg-observation-nct04836273-2023-02-02-3f1d5891cd73))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct04836273-2023-02-02-3f1d5891cd73`](#source-ctg-observation-nct04836273-2023-02-02-3f1d5891cd73))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct04836273-2023-02-02-3f1d5891cd73`](#source-ctg-observation-nct04836273-2023-02-02-3f1d5891cd73))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04836273-2023-02-02-3f1d5891cd73`](#source-ctg-observation-nct04836273-2023-02-02-3f1d5891cd73))

### Sources

<a id="source-ctg-observation-nct04836273-2023-02-02-3f1d5891cd73"></a>
- **ClinicalTrials.gov record NCT04836273 · retained source version 2023-02-02:3f1d5891cd73aca0b55e32dc8e40a891059ab82131e6b14b201fcdbe95987d28** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04836273) (`ctg-observation-nct04836273-2023-02-02-3f1d5891cd73`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04836273." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct04836273-dasiglucagon-v1 SHA-256: 45239e22956babbdcc69617670188c0bda48de7528fa7f55b1c2250b9651a92a.

---

<a id="clinicaltrials-gov-nct05378672-dasiglucagon-v1"></a>

## ClinicalTrials.gov record NCT05378672

> PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon.

- Evidence object: `story:clinicaltrials-gov-nct05378672-dasiglucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05378672-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct05378672-dasiglucagon-v1
- Content SHA-256: `dfa49cdbe0bd20e317508cf1135c1d8acd8798e587d487bbd655586fb3822390`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05378672 ([`ctg-observation-nct05378672-2025-07-20-9677a92d4db4`](#source-ctg-observation-nct05378672-2025-07-20-9677a92d4db4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct05378672-2025-07-20-9677a92d4db4`](#source-ctg-observation-nct05378672-2025-07-20-9677a92d4db4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon. ([`ctg-observation-nct05378672-2025-07-20-9677a92d4db4`](#source-ctg-observation-nct05378672-2025-07-20-9677a92d4db4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05378672-2025-07-20-9677a92d4db4`](#source-ctg-observation-nct05378672-2025-07-20-9677a92d4db4))

### Sources

<a id="source-ctg-observation-nct05378672-2025-07-20-9677a92d4db4"></a>
- **ClinicalTrials.gov record NCT05378672 · retained source version 2025-07-20:9677a92d4db4ad97f9c9198dd2adb53298db2966df375bdb3bec15a9867e6ce6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05378672) (`ctg-observation-nct05378672-2025-07-20-9677a92d4db4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05378672." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#clinicaltrials-gov-nct05378672-dasiglucagon-v1 SHA-256: dfa49cdbe0bd20e317508cf1135c1d8acd8798e587d487bbd655586fb3822390.

---

<a id="fda-drugs-nda214231-v1"></a>

## Drugs@FDA application NDA214231

> The official Drugs@FDA dataset lists original submission 1 for NDA 214231 with status AP dated 2021-03-22, and names dasiglucagon hydrochloride among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda214231:v1`
- Evidence domain: Regulatory
- Date in source: 2021-03-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda214231/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#fda-drugs-nda214231-v1
- Content SHA-256: `ae16c4d95839f99ede6c6825ddd0fbfb0bf0e724635ba9e5bd4764665e33be55`

### Claims and source pins

#### Headline

Drugs@FDA application NDA214231 ([`fda-drugs-nda214231-2021-03-22-be848ac772d0`](#source-fda-drugs-nda214231-2021-03-22-be848ac772d0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 214231 with status AP dated 2021-03-22, and names dasiglucagon hydrochloride among the application record's active ingredients. ([`fda-drugs-nda214231-2021-03-22-be848ac772d0`](#source-fda-drugs-nda214231-2021-03-22-be848ac772d0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 214231 with status AP dated 2021-03-22, and names dasiglucagon hydrochloride among the application record's active ingredients. ([`fda-drugs-nda214231-2021-03-22-be848ac772d0`](#source-fda-drugs-nda214231-2021-03-22-be848ac772d0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda214231-2021-03-22-be848ac772d0`](#source-fda-drugs-nda214231-2021-03-22-be848ac772d0))

### Sources

<a id="source-fda-drugs-nda214231-2021-03-22-be848ac772d0"></a>
- **Drugs@FDA application NDA214231 · original submission status AP · 2021-03-22 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA214231%22&limit=1) (`fda-drugs-nda214231-2021-03-22-be848ac772d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA214231." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#fda-drugs-nda214231-v1 SHA-256: ae16c4d95839f99ede6c6825ddd0fbfb0bf0e724635ba9e5bd4764665e33be55.

---

<a id="federal-register-2023-26260-v1"></a>

## Federal Register notice 2023-26260

> The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon.

- Evidence object: `story:federal-register-2023-26260:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-26260/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#federal-register-2023-26260-v1
- Content SHA-256: `6c1530519647c2679ac73956e997295b648a4a27b3f2eea6e4c78136230c4a6d`

### Claims and source pins

#### Headline

Federal Register notice 2023-26260 ([`federal-register-2023-26260-32619df29df3`](#source-federal-register-2023-26260-32619df29df3))

#### Summary

The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon. ([`federal-register-2023-26260-32619df29df3`](#source-federal-register-2023-26260-32619df29df3))

#### Paragraph 1

The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon. ([`federal-register-2023-26260-32619df29df3`](#source-federal-register-2023-26260-32619df29df3))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-26260-32619df29df3`](#source-federal-register-2023-26260-32619df29df3))

### Sources

<a id="source-federal-register-2023-26260-32619df29df3"></a>
- **Federal Register notice 2023-26260 · published 2023-11-30 · Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26260.pdf) (`federal-register-2023-26260-32619df29df3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-26260." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#federal-register-2023-26260-v1 SHA-256: 6c1530519647c2679ac73956e997295b648a4a27b3f2eea6e4c78136230c4a6d.

---

<a id="pubmed-pmid-33906916-dasiglucagon-v1"></a>

## Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.

> PubMed lists PMID 33906916 in Diabetes care as Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-27 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33906916-dasiglucagon:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33906916-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#pubmed-pmid-33906916-dasiglucagon-v1
- Content SHA-256: `b2a2cd97bea1e4950cda475d9405a86ca7ed35f7eed96b2d99a59d13fc0d5249`

### Claims and source pins

#### Headline

Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting. ([`pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352`](#source-pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352))

#### Summary

PubMed lists PMID 33906916 in Diabetes care as Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-27 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352`](#source-pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352))

#### Paragraph 1

PubMed lists PMID 33906916 in Diabetes care as Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-27 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352`](#source-pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352`](#source-pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352))

### Sources

<a id="source-pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352"></a>
- **Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting. · retained source version 1:2026-11-09:current:6d35707cd3523bf75d1f1a8a9b5ded6818c5455d13c452ce9619983603265b06** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33906916/) (`pubmed-observation-pmid-33906916-2026-11-09-6d35707cd352`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#pubmed-pmid-33906916-dasiglucagon-v1 SHA-256: b2a2cd97bea1e4950cda475d9405a86ca7ed35f7eed96b2d99a59d13fc0d5249.

---

<a id="pubmed-pmid-33998648-dasiglucagon-v1"></a>

## Dasiglucagon Hydrochloride.

> PubMed lists PMID 33998648 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2021-07-22 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33998648-dasiglucagon:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33998648-dasiglucagon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#pubmed-pmid-33998648-dasiglucagon-v1
- Content SHA-256: `28efb3072f9845bb28b64cf07c874c6f1ea8650bdd5995200b09c37effaf37ed`

### Claims and source pins

#### Headline

Dasiglucagon Hydrochloride. ([`pubmed-observation-pmid-33998648-2026-11-09-13af3370026a`](#source-pubmed-observation-pmid-33998648-2026-11-09-13af3370026a))

#### Summary

PubMed lists PMID 33998648 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2021-07-22 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33998648-2026-11-09-13af3370026a`](#source-pubmed-observation-pmid-33998648-2026-11-09-13af3370026a))

#### Paragraph 1

PubMed lists PMID 33998648 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2021-07-22 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33998648-2026-11-09-13af3370026a`](#source-pubmed-observation-pmid-33998648-2026-11-09-13af3370026a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33998648-2026-11-09-13af3370026a`](#source-pubmed-observation-pmid-33998648-2026-11-09-13af3370026a))

### Sources

<a id="source-pubmed-observation-pmid-33998648-2026-11-09-13af3370026a"></a>
- **Dasiglucagon Hydrochloride. · retained source version 1:2026-11-09:current:13af3370026a9336522d6d6dc224331c93278ab4ed1222e87e7a8c94b15ac3f6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33998648/) (`pubmed-observation-pmid-33998648-2026-11-09-13af3370026a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dasiglucagon Hydrochloride." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dasiglucagon.json#pubmed-pmid-33998648-dasiglucagon-v1 SHA-256: 28efb3072f9845bb28b64cf07c874c6f1ea8650bdd5995200b09c37effaf37ed.

